Stock listing
KRX:068760 Celltrion Pharm Inc. (셀트리온제약) 주가
Follow Celltrion Pharm Inc. into a list and get an email when it puts out news.
Share price · KRX:068760
₩40,650 KRW +400 (+1.0%)
Close on Nov 20, 2026
- Day range
- ₩40,500 – ₩41,250 KRWNov 20, 2026
- Volume
- 44,287 sharesNov 20, 2026
- Market cap
- ₩1.80T KRWAt the close on Nov 20, 2026 · price × 44.26M shares outstanding
- 52-week range
- ₩35,600 – ₩78,300 KRWLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- ₩2.89B KRWMedian day 60,470 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · KRX:068760 · KRW, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ₩40,650 | +400 | +1.0% | ₩41,150 | ₩41,250 | ₩40,500 | 44,287 | |
| ₩40,250 | -750 | -1.8% | ₩40,650 | ₩41,700 | ₩40,150 | 64,961 | |
| ₩41,000 | +600 | +1.5% | ₩40,400 | ₩41,900 | ₩40,300 | 70,536 | |
| ₩40,400 | -700 | -1.7% | ₩41,500 | ₩41,950 | ₩39,950 | 78,209 | |
| ₩41,100 | +850 | +2.1% | ₩41,100 | ₩42,500 | ₩40,850 | 85,040 | |
| ₩40,250 | -1,050 | -2.5% | ₩41,050 | ₩42,000 | ₩40,250 | 72,901 | |
| ₩41,300 | +1,700 | +4.3% | ₩40,000 | ₩43,000 | ₩39,950 | 156,191 | |
| ₩39,600 | +200 | +0.5% | ₩39,900 | ₩41,275 | ₩39,350 | 90,006 | |
| ₩39,400 | -200 | -0.5% | ₩39,300 | ₩40,950 | ₩39,150 | 112,602 | |
| ₩39,600 | -750 | -1.9% | ₩38,450 | ₩40,500 | ₩38,050 | 125,783 | |
| ₩40,350 | +2,500 | +6.6% | ₩39,000 | ₩40,450 | ₩38,650 | 154,060 | |
| ₩37,850 | +1,150 | +3.1% | ₩37,250 | ₩37,850 | ₩36,250 | 68,863 | |
| ₩36,700 | -350 | -0.9% | ₩36,700 | ₩37,450 | ₩36,550 | 33,809 | |
| ₩37,050 | +400 | +1.1% | ₩36,550 | ₩37,450 | ₩36,200 | 23,317 | |
| ₩36,650 | -150 | -0.4% | ₩36,650 | ₩37,600 | ₩36,000 | 37,398 | |
| ₩36,800 | -300 | -0.8% | ₩37,450 | ₩37,500 | ₩36,300 | 47,099 | |
| ₩37,100 | +550 | +1.5% | ₩36,700 | ₩37,600 | ₩36,700 | 33,016 | |
| ₩36,550 | +50 | +0.1% | ₩36,750 | ₩37,550 | ₩36,200 | 51,525 | |
| ₩36,500 | -1,100 | -2.9% | ₩37,150 | ₩37,600 | ₩36,450 | 39,896 | |
| ₩37,600 | -1,000 | -2.6% | ₩38,200 | ₩38,250 | ₩37,550 | 41,591 | |
| ₩38,600 | -750 | -1.9% | ₩38,950 | ₩39,800 | ₩38,400 | 56,304 | |
| ₩39,350 | -50 | -0.1% | ₩40,250 | ₩40,850 | ₩39,100 | 47,696 | |
| ₩39,400 | -600 | -1.5% | ₩39,500 | ₩40,550 | ₩39,350 | 59,449 | |
| ₩40,000 | +1,100 | +2.8% | ₩38,600 | ₩40,000 | ₩38,550 | 47,021 | |
| ₩38,900 | +2,350 | +6.4% | ₩36,550 | ₩39,550 | ₩36,550 | 93,803 | |
| ₩36,550 | -800 | -2.1% | ₩36,650 | ₩36,950 | ₩35,600 | 82,216 | |
| ₩37,350 | -200 | -0.5% | ₩37,200 | ₩38,150 | ₩37,150 | 56,922 | |
| ₩37,550 | -750 | -2.0% | ₩36,950 | ₩37,850 | ₩36,400 | 92,504 | |
| ₩38,300 | -500 | -1.3% | ₩38,950 | ₩39,800 | ₩38,200 | 57,212 | |
| ₩38,800 | -1,300 | -3.2% | ₩39,850 | ₩40,500 | ₩38,800 | 52,164 | |
| ₩40,100 | +450 | +1.1% | ₩39,950 | ₩40,600 | ₩39,700 | 45,381 | |
| ₩39,650 | +1,250 | +3.3% | ₩38,650 | ₩40,150 | ₩38,600 | 80,558 | |
| ₩38,400 | -1,250 | -3.2% | ₩39,500 | ₩39,750 | ₩38,250 | 99,025 | |
| ₩39,650 | +1,550 | +4.1% | ₩37,900 | ₩39,650 | ₩37,800 | 120,590 | |
| ₩38,100 | -500 | -1.3% | ₩38,500 | ₩38,650 | ₩37,950 | 91,304 | |
| ₩38,600 | -750 | -1.9% | ₩39,300 | ₩39,300 | ₩38,050 | 116,563 | |
| ₩39,350 | +300 | +0.8% | ₩39,250 | ₩39,900 | ₩38,900 | 113,068 | |
| ₩39,050 | +250 | +0.6% | ₩38,950 | ₩39,200 | ₩38,700 | 34,703 | |
| ₩38,800 | -700 | -1.8% | ₩39,550 | ₩39,750 | ₩38,750 | 37,004 | |
| ₩39,500 | +400 | +1.0% | ₩39,150 | ₩39,700 | ₩38,900 | 40,072 | |
| ₩39,100 | -100 | -0.3% | ₩39,700 | ₩39,800 | ₩38,400 | 400,420 | |
| ₩39,200 | +400 | +1.0% | ₩38,850 | ₩39,300 | ₩38,700 | 46,546 | |
| ₩38,800 | -450 | -1.1% | ₩39,300 | ₩39,450 | ₩38,750 | 42,153 | |
| ₩39,250 | -150 | -0.4% | ₩39,150 | ₩40,000 | ₩39,100 | 41,184 | |
| ₩39,400 | 0 | 0.0% | ₩38,800 | ₩39,700 | ₩38,600 | 53,996 | |
| ₩39,400 | -600 | -1.5% | ₩39,400 | ₩39,900 | ₩39,150 | 68,923 | |
| ₩40,000 | -250 | -0.6% | ₩39,800 | ₩40,300 | ₩39,650 | 78,378 | |
| ₩40,250 | +250 | +0.6% | ₩39,900 | ₩40,350 | ₩39,700 | 43,630 | |
| ₩40,000 | -550 | -1.4% | ₩40,550 | ₩40,800 | ₩40,000 | 59,182 | |
| ₩40,550 | -300 | -0.7% | ₩41,250 | ₩41,250 | ₩40,350 | 43,795 | |
| ₩40,850 | 0 | 0.0% | ₩41,050 | ₩41,900 | ₩40,750 | 47,726 | |
| ₩40,850 | -300 | -0.7% | ₩41,550 | ₩42,000 | ₩40,750 | 53,601 | |
| ₩41,150 | -400 | -1.0% | ₩41,300 | ₩42,150 | ₩40,650 | 77,116 | |
| ₩41,550 | -150 | -0.4% | ₩41,650 | ₩42,150 | ₩41,300 | 61,490 | |
| ₩41,700 | -900 | -2.1% | ₩42,200 | ₩42,200 | ₩40,850 | 98,719 | |
| ₩42,600 | +600 | +1.4% | ₩41,700 | ₩42,800 | ₩41,500 | 47,920 | |
| ₩42,000 | -550 | -1.3% | ₩42,200 | ₩42,950 | ₩41,950 | 77,021 | |
| ₩42,550 | +550 | +1.3% | ₩42,200 | ₩42,800 | ₩41,900 | 63,646 | |
| ₩42,000 | -800 | -1.9% | ₩41,800 | ₩42,800 | ₩41,050 | 67,471 | |
| ₩42,800 | +1,250 | +3.0% | ₩41,600 | ₩43,350 | ₩41,600 | 74,974 | |
| ₩41,550 | -1,400 | -3.3% | ₩42,150 | ₩42,200 | ₩40,900 | 56,219 | |
| ₩42,950 | +1,800 | +4.4% | ₩42,550 | ₩43,350 | ₩42,150 | 65,190 |
Splits
7 splits since 2014 · KRX:068760 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 21-for-20 | Split | |
| 21-for-20 | Split | |
| 51-for-50 | Split | |
| 21-for-20 | Split | |
| 21-for-20 | Split | |
| 103-for-100 | Split | |
| 21-for-20 | Split |
- Ticker
- KRX:068760
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- KRX
- Currency
- KRW
Latest news
Celltrion Pharm Inc. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 3 in all · newest Sep 17, 2025 · oldest 2019
Valuation
P/E 42.0× against a median of 23.6×: 6th lowest of 8 Pharmaceuticals companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- ₩1.68T KRW
- P/E
- 42.0×
- EV/sales
- 2.9×
- EV/EBITDA
- 19.6×
- Price/book
- 4.0×
- Gross margin
- 31.1%
- Operating margin
- 10.7%
- Net margin
- 7.4%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Celltrion Pharm Inc. · KRX:068760 | US$1.34B | US$1.25B | 42.0× | 2.9× | 19.6× | 4.0× | 7.4% | 0.0× | n/a |
| Zhejiang Medicine Co., Ltd. Class A · SSE:600216 | US$1.47B | US$973.2M | 15.5× | 0.8× | n/a | 0.8× | 7.5% | 0.0× | n/a |
| Yantai Dongcheng Biochemicals Co., Ltd. Class A · SZSE:002675 | US$1.46B | US$1.41B | 46.5× | 3.6× | n/a | 2.2× | 8.0% | 0.1× | n/a |
| Fujian Haixi Pharmaceuticals Co., Ltd. Class H · HKEX:2637 | US$1.45B | US$1.27B | 54.6× | 14.6× | 41.3× | 5.8× | 30.4% | 0.0× | n/a |
| Marksans Pharma Limited · NSE:MARKSANS | US$1.42B | US$1.35B | 23.6× | 3.7× | 16.0× | 4.0× | 16.5% | 0.1× | n/a |
| Zhejiang Jingxin Pharmaceutical Co., Ltd. Class A · SZSE:002020 | US$1.40B | US$1.23B | 13.2× | 2.0× | n/a | 1.6× | 17.5% | 0.0× | n/a |
| Chengdu Olymvax Biopharmaceuticals Inc. Class A · SSE:688319 | US$1.37B | US$1.39B | n/a | 11.7× | n/a | 10.2× | −4.0% | 0.4× | n/a |
| Innoviva, Inc. · NASDAQ:INVA | US$1.33B | US$998.8M | 6.9× | 2.3× | 4.7× | 1.2× | 44.1% | 0.2× | 0.29 |
| Tianjin Chase Sun Pharmaceutical Co., Ltd. Class A · SZSE:300026 | US$1.30B | US$1.07B | n/a | n/a | n/a | 1.0× | n/a | 0.0× | n/a |
| Zhejiang Hisoar Pharmaceutical Co., Ltd. Class A · SZSE:002099 | US$1.30B | US$1.17B | n/a | 3.9× | n/a | 1.9× | −11.6% | 0.0× | n/a |
| Concord Biotech Ltd. · NSE:CONCORDBIO | US$1.24B | US$1.19B | 40.6× | 9.4× | 27.3× | 5.5× | 24.1% | 0.0× | n/a |
| Median of the others | US$1.39B | US$1.21B | 23.6× | 3.7× | 21.6× | 2.0× | 16.5% | 0.0× | 0.29 |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q1 2026 | May 13, 2026 · Before open | −2.7% |
| Q4 2025 | Mar 16, 2026 · Before open | −1.6% |
| Q2 2025 | Aug 12, 2025 · Before open | −0.2% |
| Q1 2025 | May 15, 2025 · Before open | −0.5% |
| Q4 2024 | Mar 17, 2025 · After close | +0.9% |
| Q2 2024 | Aug 14, 2024 · After close | −1.8% |
| Q1 2024 | May 16, 2024 · After close | −2.9% |
| Q4 2023 | Mar 18, 2024 · After close | +1.6% |
| Q3 2023 | Nov 14, 2023 · After close | +9.5% |
| Q2 2023 | Aug 13, 2023 · After close | −9.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2023 | May 12, 2023 · After close | −0.3% |
| Q4 2022 | Mar 20, 2023 · After close | −1.4% |
| Q3 2022 | Nov 14, 2022 · After close | +3.6% |
| Q2 2022 | Aug 16, 2022 · Before open | +0.1% |
| Q1 2022 | May 13, 2022 · Before open | −2.8% |
| Q4 2021 | Mar 8, 2022 · Before open | +1.6% |
| Q3 2021 | Nov 15, 2021 | +14.6% |
| Quarter to Jun 30, 2021 | Aug 17, 2021 | +2.3% |
| Quarter to Mar 31, 2021 | May 14, 2021 | +2.8% |
| Quarter to Dec 31, 2020 | Mar 18, 2021 | −1.4% |
Financials
Annual, in KRW
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 536.4B | 477.8B | 388.8B | 386.0B | 398.7B | 233.6B | 173.5B | 146.9B | 135.9B | 104.8B |
| Cost of revenue | 372.6B | 355.8B | 269.1B | 273.3B | 279.5B | 160.4B | 111.0B | 106.3B | 77.6B | 52.6B |
| Gross profit | 163.8B | 122.0B | 119.7B | 112.8B | 119.3B | 73.2B | 62.5B | 40.6B | 58.3B | 52.2B |
| Research and development | 19.1B | 13.0B | 12.7B | 8.00B | 6.37B | 4.61B | 2.16B | 1.92B | 1.03B | 1.20B |
| Selling, general and administrative | 41.9B | 68.1B | 68.2B | 65.5B | 64.1B | 43.5B | 43.9B | 33.8B | 47.3B | 42.4B |
| Operating income | 56.1B | 37.2B | 33.4B | 38.2B | 47.8B | 23.6B | 14.4B | -332.9M | 8.67B | 7.27B |
| Depreciation and amortization | 22.2B | 19.2B | 18.7B | 16.8B | 15.8B | 13.5B | 13.0B | 12.7B | 12.2B | 8.99B |
| EBITDA | 78.3B | 56.5B | 52.1B | 54.9B | 63.6B | 37.1B | 27.5B | 12.4B | 20.9B | 16.3B |
| Interest expense | 6.67B | 7.51B | 8.29B | 6.22B | 5.36B | 4.58B | 5.04B | 0 | 0 | 0 |
| Income before tax | 49.7B | 29.8B | 26.2B | 30.5B | 42.5B | 20.1B | 8.84B | -6.26B | 2.46B | 571.8M |
| Income tax | -811.8M | 242.7M | 3.13B | -251.2M | -2.34B | |||||
| Net income | 38.8B | 22.0B | 21.3B | 26.0B | 34.6B | 20.9B | 8.60B | -9.39B | 2.71B | 2.92B |
| Earnings per share, basic | 874.86 | 505.39 | 489.01 | 596.73 | 876.55 | 557.20 | 228.91 | -250.01 | 72.39 | 77.97 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 49.9B | 45.5B | 19.7B | 31.4B | 80.2B | 25.7B | 10.8B | 9.12B | 5.64B | 10.2B |
| Short-term investments | 67.1B | 18.0B | 12.5B | 12.7B | 7.97B | 4.00B | 2.57B | 315.0M | 315.0M | |
| Receivables | 220.3B | 213.2B | 222.2B | 185.9B | 172.5B | 140.5B | 139.5B | 133.3B | 125.6B | 81.8B |
| Inventory | 122.9B | 101.4B | 100.4B | 69.2B | 63.9B | 55.0B | 33.1B | 42.0B | 65.2B | 78.9B |
| Current assets | 470.6B | 391.7B | 364.8B | 311.9B | 331.1B | 231.0B | 188.9B | 200.0B | 211.1B | 184.8B |
| Property, plant and equipment | 222.7B | 220.8B | 228.2B | 241.9B | 248.3B | 216.6B | 195.6B | 199.9B | 209.8B | |
| Goodwill | 32.9B | 32.9B | 32.9B | 32.9B | 32.9B | 32.9B | 32.9B | 32.9B | 32.9B | 32.9B |
| Total assets | 759.4B | 669.5B | 641.6B | 599.7B | 637.9B | 548.1B | 471.0B | 452.4B | 470.3B | 510.0B |
| Accounts payable | 78.7B | 46.7B | 59.3B | 38.1B | 72.6B | 21.6B | 6.81B | 12.4B | 13.2B | 12.8B |
| Current liabilities | 283.6B | 247.7B | 249.3B | 212.0B | 259.9B | 184.9B | 149.1B | 145.0B | 124.3B | 72.4B |
| Long-term debt | 0 | 4.33B | 21.7B | 39.0B | 57.3B | 38.6B | 34.4B | 48.1B | 89.0B | |
| Total debt | 178.9B | 147.8B | 133.2B | 137.4B | 138.7B | |||||
| Total liabilities | 323.5B | 272.5B | 265.0B | 242.9B | 305.9B | 247.5B | 190.9B | 182.4B | 176.6B | 165.4B |
| Shareholders' equity | 436.0B | 396.9B | 376.7B | 356.8B | 332.0B | 300.6B | 280.0B | 270.0B | 293.6B | 344.6B |
| Shares outstanding | 44.3M | 43.5M | 43.5M | 43.5M | 39.4M | 37.6M | 37.6M | 37.6M | 37.5M | 37.4M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 86.4B | 56.6B | 8.76B | -4.05B | 93.2B | 36.2B | 27.9B | 14.3B | -10.2B | -15.2B |
| Capital spending | -17.9B | -5.98B | -6.90B | -6.29B | -12.5B | -42.0B | -30.5B | -7.21B | -1.08B | -2.19B |
| Free cash flow | 68.5B | 50.6B | 1.86B | -10.3B | 80.6B | -8.01B | -2.63B | 7.11B | -11.2B | -17.4B |
| Cash from investing | -12.1B | -4.22B | -14.6B | -16.3B | -44.9B | -34.5B | -7.33B | -1.01B | -8.63B | |
| Cash from financing | -18.7B | -16.2B | -30.2B | -22.4B | 23.6B | 8.26B | -3.51B | 6.65B | 24.3B | |
| Share buybacks | -2.44B | -4.05B | -3.72B | -3.71B | -4.29B | -832.2M | 255.8M | -382.7M | 1.01B | 898.0M |
| Change in cash | 4.39B | 25.8B | -11.7B | -48.8B | 54.4B | 15.0B | 1.65B | 3.48B | -4.56B | 493.1M |
Cap table
Built by 6ix from Celltrion Pharm Inc.’s releases
- Common shares
- 44,258,079
- Fully diluted
- 44,258,079
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 44,258,079 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 44,258,079 |
Log in to ask 6ix AI your own questions about Celltrion Pharm Inc.